Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Rolapitant (Varubi) is indicated in combination with other antiemetic agents for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.
• Two studies were reviewed that discussed the effectiveness and safety of various antiemetic drugs, including Varubi.
• In terms of preventing Chemotherapy-induced Nausea and Vomiting (CINV), combinations involving newer NK1 antagonists like Varubi combined with granisetron showed moderate certainty in providing complete control of vomiting but were less efficacious than some reference combinations. However, it was more effective than granisetron alone when used for moderately emetogenic chemotherapy.
• Regarding safety during CINV treatment, fewer participants may experience serious adverse events (SAEs) with some combinations than others; specifically, a combination therapy involving Varubi showed potentially lower SAEs but this conclusion has low certainty.
• For Postoperative Nausea and Vomiting (PONV), NK1 receptor antagonists like Varubi were among the drugs showing clinically important benefits compared to placebo although specific data on its efficacy wasn't provided directly.
• The studies underscored an absence of one-size-fits-all treatment in preventing nausea/vomiting due to chemotherapy or post-operation conditions, which highlights a need for personalized approaches based on patient characteristics as well as their respective medical procedures or treatments.